Autor según el artículo: Perpinan, Carles; Bertran, Laia; Terra, Ximena; Aguilar, Carmen; Lopez-Dupla, Miguel; Alibalic, Ajla; Riesco, David; Camaron, Javier; Perrone, Francesco; Rull, Anna; Reverte, Laia; Yeregui, Elena; Marti, Anna; Vidal, Francesc; Auguet, Teresa
Departamento: Medicina i Cirurgia
e-ISSN: 2075-4426
Autor/es de la URV: Aguilar Crespillo, Carmen Isabel / Alibalic, Ajla / Auguet Quintillà, Maria Teresa / Bertran Ramos, Laia / Camarón Mallén, Javier Mariano / López Dupla, Jesús Miguel / Martí Zaragoza, Àlex / RULL AIXA, ANNA / Terra Barbadora, Ximena / Vidal Marsal, Francisco / Yeregui Etxeberria, Elena
Palabras clave: Sars-cov-2 Prediction Pneumonia Personalized therapy Obesity Metabolic syndrome Covid-19
Resumen: In SARS-CoV-2-infected patients, obesity, hypertension, and diabetes are dangerous factors that may result in death. Priority in detection and specific therapies for these patients are necessary. We wanted to investigate the impact of obesity and metabolic syndrome (MS) on the clinical course of COVID-19 and whether prognostic biomarkers described are useful to predict the evolution of COVID-19 in patients with obesity or MS. This prospective cohort study included 303 patients hospitalized for COVID-19. Participants were first classified according to the presence of obesity; then, they were classified according to the presence of MS. Clinical, radiologic, and analytical parameters were collected. We reported that patients with obesity presented moderate COVID-19 symptoms and pneumonia, bilateral pulmonary infiltrates, and needed tocilizumab more frequently. Meanwhile, patients with MS presented severe pneumonia and respiratory failure more frequently, they have a higher mortality rate, and they also showed higher creatinine and troponin levels. The main findings of this study are that IL-6 is a potential predictor of COVID-19 severity in patients with obesity, while troponin and LDH can be used as predictive biomarkers of COVID-19 severity in MS patients. Therefore, treatment for COVID-19 in patients with obesity or MS should probably be intensified and personalized.
Áreas temáticas: Science and technology studies Medicine, general & internal Medicine (miscellaneous) Health care sciences & services
Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
Direcció de correo del autor: javiermariano.camaron@urv.cat ajla.alibalic@estudiants.urv.cat elena.yeregui@estudiants.urv.cat alex.marti@estudiants.urv.cat laia.bertranr@estudiants.urv.cat laia.bertranr@estudiants.urv.cat ximena.terra@urv.cat carmenisabel.aguilar@urv.cat carmenisabel.aguilar@urv.cat mariateresa.auguet@urv.cat francesc.vidal@urv.cat jesusmiguel.lopez@urv.cat
Identificador del autor: 0000-0001-9052-1368 0000-0001-9052-1368 0000-0003-1043-5844 0000-0002-4440-562X 0000-0002-4440-562X 0000-0003-0396-6428 0000-0002-6692-6186 0000-0002-9141-2523
Fecha de alta del registro: 2024-09-28
Volumen de revista: 11
Versión del articulo depositado: info:eu-repo/semantics/publishedVersion
Enlace a la fuente original: https://www.mdpi.com/2075-4426/11/3/227
URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/
Referencia al articulo segun fuente origial: J Pers Med. 11 (3): 227-
Referencia de l'ítem segons les normes APA: Perpinan, Carles; Bertran, Laia; Terra, Ximena; Aguilar, Carmen; Lopez-Dupla, Miguel; Alibalic, Ajla; Riesco, David; Camaron, Javier; Perrone, Frances (2021). Predictive biomarkers of COVID-19 severity in SARS-CoV-2 infected patients with obesity and metabolic syndrome. J Pers Med, 11(3), 227-. DOI: 10.3390/jpm11030227
DOI del artículo: 10.3390/jpm11030227
Entidad: Universitat Rovira i Virgili
Año de publicación de la revista: 2021
Tipo de publicación: Journal Publications